Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults A randomized open-label trial

被引:29
|
作者
Juergens, Christine [1 ]
de Villiers, Pierre J. T. [2 ]
Moodley, Keymanthri [2 ]
Jayawardene, Deepthi [3 ]
Jansen, Kathrin U. [3 ]
Scott, Daniel A. [3 ]
Emini, Emilio A. [3 ]
Gruber, William C. [3 ]
Schmoele-Thoma, Beate [1 ]
机构
[1] Pfizer GmbH, Berlin, Germany
[2] Univ Stellenbosch, ZA-7505 Tygerberg, South Africa
[3] Pfizer Inc, Pearl River, NY USA
关键词
13-valent pneumococcal conjugate vaccine; 23-valent pneumococcal polysaccharide vaccine; adults; elderly; immunogenicity; PCV13; PPSV23; safety; OPSONOPHAGOCYTIC ASSAY; RESPONSES;
D O I
10.4161/hv.27998
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
This randomized open-label trial was designed to provide preliminary immunogenicity and safety data to support development of the pediatric 13-valent pneumococcal conjugate vaccine (PCV13) for adults. The aims were to: identify an age-appropriate PCV13 formulation, i.e., with (n = 309) or without (n = 304) aluminum phosphate (AlPO4); compare the selected PCV13 formulation (n = 309) with 23-valent pneumococcal polysaccharide vaccine (PPSV23; n = 301); and, together with an extension study, assess sequential use of pneumococcal vaccines at 1-year intervals in adults aged >= 65 years (n = 105) not pre-vaccinated with PPSV23. Immune responses were measured by ELISA and opsonophagocytic activity assays 1 month postvaccination. Immunoglobulin G responses elicited by PCV13 with AlPO4 and PCV13 without AlPO4 were similar for the majority, and noninferior for all PCV13 serotypes. PCV13 with AlPO4 was generally more reactogenic, with reactions mainly mild or moderate. Thus, PCV13 with AlPO4 (hereafter PCV13) became the selected formulation. Immune responses to PCV13 were noninferior for all but one serotype and for most PCV13 serotypes superior to PPSV23. Vaccine sequence assessments showed that for PCV13/PPSV23, the initial PCV13 dose generally enhanced responses to a subsequent PPSV23 dose, compared with PPSV23 alone. For PCV13/PCV13, a second dose did not enhance the first dose response when given after 1 year. For PCV13/PPSV23/PCV13, priming with PCV13 (vaccination 1) did not protect against lower responses induced by PPSV23 to subsequent PCV13 (vaccination 3). In conclusion, the pediatric PCV13 formulation with AlPO4 is well tolerated and immunogenic in adults, is generally more immunogenic than PPSV23, and subsequent vaccination with PPSV23 is possible if required.
引用
收藏
页码:1343 / 1353
页数:11
相关论文
共 50 条
  • [41] Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in infants: A meta-analysis
    Ruiz-Aragon, J.
    Marquez Pelaez, S.
    Molina-Linde, J. M.
    Grande-Tejada, A. M.
    VACCINE, 2013, 31 (46) : 5349 - 5358
  • [42] 13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): A phase 3, open-label trial
    Silfverdal, Sven Arne
    Flodmark, Carl-Erik
    Rombo, Lars
    Tansey, Susan P.
    Sidhu, Mohinder
    Trammel, James
    Emini, Emilio A.
    Gruber, William C.
    Scott, Daniel A.
    Gurtman, Alejandra
    VACCINE, 2013, 31 (09) : 1284 - 1292
  • [43] Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea
    Kang, Dong-Won
    Kim, Chae-Rin
    Song, Joon Young
    Park, Sun-Kyeong
    VACCINE, 2024, 42 (04) : 871 - 878
  • [44] Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults
    Scott, Daniel A.
    Komjathy, Steven F.
    Hu, Branda T.
    Baker, Sherryl
    Supan, Lois A.
    Monahan, Carol A.
    Gruber, William
    Siber, George R.
    Lockhart, Stephen P.
    VACCINE, 2007, 25 (33) : 6164 - 6166
  • [45] Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial
    Nakashima, Kei
    Aoshima, Masahiro
    Ohfuji, Satoko
    Yamawaki, Satoshi
    Nemoto, Masahiro
    Hasegawa, Shinya
    Noma, Satoshi
    Misawa, Masafumi
    Hosokawa, Naoto
    Yaegashi, Makito
    Otsuka, Yoshihito
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (08) : 1923 - 1930
  • [46] A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants
    Platt, Heather L.
    Greenberg, David
    Tapiero, Bruce
    Clifford, Robert A.
    Klein, Nicola P.
    Hurley, David C.
    Shekar, Tulin
    Li, Jianing
    Hurtado, Kim
    Su, Shu-Chih
    Nolan, Katrina M.
    Acosta, Camilo J.
    McFetridge, Richard D.
    Bickham, Kara
    Musey, Luwy K.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2020, 39 (08) : 763 - 770
  • [47] A phase III clinical trial to evaluate the safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine (PPV23) in healthy children, adults, and elderly
    Huang, Lili
    Wang, Ling
    Li, Hong
    Hu, Yuansheng
    Ru, Weiping
    Han, Weixiao
    Shi, Gang
    Ye, Qiang
    Han, Zhen
    Xia, Jielai
    Xia, Shengli
    Xu, Miao
    Li, Jing
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (01) : 249 - 255
  • [48] Immunogenicity and safety of the 13-valent Pneumococcal Conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naive and pre-immunized patients under treatment with chronic haemodialysis: a longitudinal quasi-experimental phase IV study
    Vandecasteele, S. J.
    De Bacquer, D.
    Caluwe, R.
    Ombelet, S.
    Van Vlem, B.
    CLINICAL MICROBIOLOGY AND INFECTION, 2018, 24 (01) : 65 - 71
  • [49] Antigen-Specific B-Cell Response to 13-Valent Pneumococcal Conjugate Vaccine in Asplenic Individuals With β-Thalassemia Previously Immunized With 23-Valent Pneumococcal Polysaccharide Vaccine
    Papadatou, Ioanna
    Piperi, Cristina
    Alexandraki, Krystallenia
    Kattamis, Antonis
    Theodoridou, Maria
    Spoulou, Vana
    CLINICAL INFECTIOUS DISEASES, 2014, 59 (06) : 862 - 865
  • [50] A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly
    Dirmesropian, S.
    Wood, J. G.
    MacIntyre, C. R.
    Newall, A. T.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (04) : 818 - 825